There is no currently available Continuous process for end-to-end mRNA synthesis for vaccines.
The proposed solution leverages CAMERNA, a novel continuous automated manufacturing system, to enable end-to-end production of mRNA drug substance. This continuous, modular approach eliminates the need for DNase, reduces reagent usage, and supports scalable, low-cost, on-demand mRNA vaccine manufacturing.
Accelerated mRNA Vaccine Development
Reduction in Cost-of-Goods
By implementing the CAMERNA continuous mRNA manufacturing system, an organization could reduce cost-of-goods by up to 1000-fold through decreased reagent usage, elimination of DNase and plasmid DNA requirements, and conservation of single-stranded DNA templates, enabling highly automated, scalable, and cost-effective mRNA production with minimal labor and facility footprint.
Optimized Affinity Resin
In virto Transcription (IVT) optimization
Integration of sensor and control system
Continuous test run
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Sepragen Corporation
University of Massachusetts Lowell
